News | May 30, 2025
Alkem reports 7.1% YoY revenue growth in Q4 FY25
Annual EBITDA margin expands by 170 basis points
Annual EBITDA margin expands by 170 basis points
For FY25, Revenue from operation grew 28.8 per cent YoY to Rs. 70.1 crore
Akums invested Rs. 272 crore in capital expenditure during FY25
Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth
Lupin is set to become first Indian company to fully integrate Honeywell’s Solstice® Air in its respiratory inhalers at scale, redefining respiratory care with near-zero global warming potential propellants
IICP is a registered charitable society working in the disability sector since 1974
CRL shall invest another Rs. 200 crore for creation of additional beds
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
30th Lab in Thyrocare’s expanding network to bring advanced, affordable diagnostics in Bihar and beyond
Subscribe To Our Newsletter & Stay Updated
